Safety of IFNa Kinoid in Systemic Lupus Erythematosus

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

March 31, 2010

Primary Completion Date

April 30, 2011

Study Completion Date

June 30, 2016

Conditions
Systemic Lupus Erythematosus
Interventions
BIOLOGICAL

IFN-K

3 to 4 IM injections over 3 months

Trial Locations (15)

1211

Geneva University Hospital, Geneva

34295

Hopital Lapeyronie, Montpellier

59037

Hopital Claude Huriez, Lille

Unknown

Cliniques Universitaires St Luc, Brussels

"MHAT Sveti Ivan Rilski", Sofia

University Hospital Split, Split

KBC Zagreb, Zagreb

Hopital de la Pitie Salpetriere, Paris

Hopital du Kremlin Bicetre, Paris

Hopital Haut-Leveque, Pessac

Kerckhoff-Klinik Gmbh, Bad Nauheim

Charite, Berlin

Inselspital, Bern

Geneva University Hospital, Geneva

Centre Hospitalier Universitaire Vaudois, Lausanne

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Neovacs

INDUSTRY

NCT01058343 - Safety of IFNa Kinoid in Systemic Lupus Erythematosus | Biotech Hunter | Biotech Hunter